RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
NEUROLOGY AND THERAPY
Collezione AOU San Luigi di Orbassano

Items : 9

Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project. in Neurology and therapy / Neurol Ther. 2024 Oct;13(5):1415-1430. doi: 10.1007/s40120-024-00644-3. Epub 2024 Aug 2.

2024
AOU San Luigi di Orbassano

Paolicelli D; Borriello G; Clerici R; Colombo E; Croce D; D'Amico E; De Rossi N; Di Sapio A; Fenu G; Maimone D; Marfia GA; Moccia M; Perini P; Piscaglia MG; Razzolini L; Riccaboni M; Signoriello E; Agostoni G; Farina A; Mondino M; Berruto F; Tettamanti A; Donnaloja F; Tortorella C;

Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study. in Neurology and therapy / Neurol Ther. 2023 Aug;12(4):1375-1383. doi: 10.1007/s40120-023-00481-w. Epub 2023 May 11.

2023
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Capobianco MA; Pautasso M; Bertolotto A; Valentino P; Martire S; Sala A; Sperli F; Malentacchi M; Malucchi S; Bruschi N;

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients. in Neurology and therapy / Neurol Ther. 2020 Dec;9(2):197-203. doi: 10.1007/s40120-020-00200-9. Epub 2020 Jun 16.

2020
AOU San Luigi di Orbassano

Bertolotto A; Martire S; Mirabile L; Capobianco M; De Gobbi M; Cilloni D;

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. in Neurology and therapy / Neurol Ther. 2020 Dec;9(2):443-457. doi: 10.1007/s40120-020-00191-7. Epub 2020 May 14.

2020
AOU San Luigi di Orbassano

Bertolotto A; Arroyo R; Celius EG; Comi G; Havrdova EK; Honeycutt WD; Hunter SF; Izquierdo G; Kornek B; Miller T; Mitsikostas DD; Singer BA; Ziemssen T; Chung L; Daizadeh N; Afsar S; Hashemi L; Senior P;

Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl(®). in Neurology and therapy / Neurol Ther. 2018 Dec;7(2):391-393. doi: 10.1007/s40120-018-0116-x. Epub 2018 Nov 10.

2018
AOU San Luigi di Orbassano

Annovazzi P; Bertolotto A; Brescia Morra V; Gasperini C; Montanari E; Navarra P; Patti F; Pia Sormani M; Ghezzi A;

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. in Neurology and therapy / Neurol Ther. 2017 Jun;6(1):145-152. doi: 10.1007/s40120-016-0058-0. Epub 2016 Dec 3.

2017
AOU San Luigi di Orbassano

Malucchi S; Capobianco M; Lo Re M; Malentacchi M; di Sapio A; Matta M; Sperli F; Bertolotto A;

A Comprehensive Review on Copemyl(®). in Neurology and therapy / Neurol Ther. 2017 Dec;6(2):161-173. doi: 10.1007/s40120-017-0079-3. Epub 2017 Jul 31.

2017
AOU San Luigi di Orbassano

Annovazzi P; Bertolotto A; Brescia Morra V; Gasperini C; Montanari E; Navarra P; Patti F; Sormani MP; Ghezzi A;

Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-? Therapy. in Neurology and therapy / Neurol Ther. 2015 Jun;4(1):53-60. doi: 10.1007/s40120-015-0027-z. Epub 2015 Mar 6.

2015
AOU San Luigi di Orbassano

Motuzova Y; Di Sapio A; Capobianco M; Sala A; Marnetto F; Malucchi S; Bertolotto A;

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. in Neurology and therapy / Neurol Ther. 2015 Dec;4(2):147-57. doi: 10.1007/s40120-015-0038-9. Epub 2015 Dec 8.

2015
AOU San Luigi di Orbassano

Lo Re M; Capobianco M; Ragonese P; Realmuto S; Malucchi S; Berchialla P; Salemi G; Bertolotto A;